eFigure 1. Response rates over time. Proportions of patients who achieved ≥ 50%, ≥ 75%, and 100% reduction in monthly migraine days (MMD) from baseline for patients in the parent double blind study receiving placebo, erenumab 7 mg, erenumab 21 mg, and erenumab 70 mg and for patients receiving erenumab 70/140 mg erenumab in the OLTP.
eFigure 2. Change in MSQ over time. Changes from baseline in mean (A) MSQ-RFR score, (B) MSQ-RFP score, (C) MSQ-EF score are shown for patients on placebo, erenumab 7 mg, erenumab 21 mg, and erenumab 70 mg during the double-blind parent study and for all patients on erenumab 70/140 mg during the OLTP. Error bars represent SE. EF, emotional function; MSQ, Migraine-Specific Quality of Life; OLTP, open-label treatment phase; RFP, role function-preventative; RFR, role function-restrictive; SE, standard error.
**eFigure 3. Change in MIDAS over time.** Changes from baseline in mean (A) MIDAS total score, (B) MIDAS presenteeism, and (C) MIDAS absenteeism are shown for patients on placebo, erenumab 7 mg, erenumab 21 mg, and erenumab 70 mg during the double-blind parent study and for all patients on erenumab 70/140 mg during the OLTP. Error bars represent SE. MIDAS, Migraine Disability Assessment; OLTP, open-label treatment phase; SE, standard error.
eTable 1. Exposure-adjusted patient incidence rates of serious adverse events during the open-label treatment phase (per 100 patient-years)

|                     | Erenumab 70 mg (N=383) | Erenumab 140 mg (N=250) | Total Erenumab (N=383) |
|---------------------|------------------------|-------------------------|------------------------|
|                     | n [r]                  | n [r]                   | n [r]                  |
| All serious AEs     | 30 [4.5]               | 21 [3.7]                | 46 [3.8]               |
| Most frequent serious AEs<sup>a</sup> |                       |                        |                        |
|  Ligament rupture   | 1 [0.1]                | 2 [0.3]                 | 3 [0.2]                |
|  Osteoarthritis     | 1 [0.1]                | 1 [0.1]                 | 2 [0.1]                |
|  Uterine leiomyoma  | 1 [0.1]                | 1 [0.1]                 | 2 [0.1]                |
|  Adjustment disorder| 1 [0.1]                | 1 [0.1]                 | 2 [0.1]                |
|  Syncope            | 2 [0.3]                | 0 [0.0]                 | 2 [0.1]                |
|  Appendicitis       | 1 [0.1]                | 2 [0.3]                 | 2 [0.1]                |
|  Deep vein thrombosis| 1 [0.1]               | 1 [0.1]                 | 2 [0.1]                |
|  Breast cancer      | 2 [0.3]                | 0 [0.0]                 | 2 [0.1]                |

AE, adverse event; n, number of patients reporting at least 1 occurrence of event; r, exposure-adjusted rate per 100 patient-years (n/e×100)

<sup>a</sup>Events with more than one occurrence
eTable 2. Development of anti-erenumab antibodies during the entire study after receiving erenumab 70 mg or 140 mg

| Patients with post-baseline results – N1 | Erenumab 70 mg/140 mg (N=401) |
|----------------------------------------|--------------------------------|
| **Baseline results, n (%)**            |                                |
| Binding antibody positive              | 0 (0.0)                        |
| Neutralizing antibody positive         | 0 (0.0)                        |
| **Post-baseline results, n (%)**       |                                |
| Binding antibody positive              | 39 (9.8)                       |
| Transient                              | 30 (76.9)                      |
| Neutralizing antibody positive         | 3 (0.8)                        |
| Transient                              | 2 (66.7)                       |
| **First occurrence of binding antibody positive relative to first erenumab 70 mg or 140 mg dose** |                                |
| Baseline to 3 months                   | 9 (2.3)                        |
| > 3 – 6 months                         | 14 (3.5)                       |
| > 6 – 9 months                         | 5 (1.3)                        |
| > 9 – 12 months                        | 7 (1.8)                        |
| > 12 – 18 months                       | 1 (0.3)                        |
| > 18 – 24 months                       | 2 (0.5)                        |
| > 24 – 36 months                       | 0 (0.0)                        |
| > 36 – 48 months                       | 1 (0.3)                        |
| > 48 months                            | 0 (0.0)                        |

*a*Negative antibody result at the last time point tested for the patient; percentage based on patients with a post-baseline binding or neutralizing antibody. One patient withdrew from the study so subsequent neutralizing antibody status could not be determined.